Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients.

Authors

Zeynep Bas, Wills Eye Hospital, Thomas Jefferson UniversityFollow
Lauren A. Dalvin, Wills Eye Hospital, Thomas Jefferson University; Mayo ClinicFollow
Sameeksha Tadepalli, Wills Eye Hospital, Thomas Jefferson University
Raksha Rao, Wills Eye Hospital, Thomas Jefferson University
Amish Shah, Children's Hospital of Philadelphia
Ann M. Leahey, Children's Hospital of Philadelphia
Carol L. Shields, Wills Eye Hospital, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

8-2021

Comments

This article is the authors’ final published version in Asia-Pacific Journal of Ophthalmology, Volume 10, Issue 4, July/August 2021, Pages 373-380.

The published version is available at https://doi.org/10.1097/APO.0000000000000360. Copyright © Bas et al.

Abstract

PURPOSE: To evaluate retinoblastoma control after intravenous chemotherapy (chemoreduction) by patient age at presentation.

DESIGN: Retrospective case series.

METHODS: This study included 964 eyes of 554 patients treated with chemoreduction at Ocular Oncology Service at Wills Eye Hospital. Patients received 6 monthly cycles of standard chemoreduction. Additional therapies for tumor control were performed as needed.

RESULTS: Of 964 eyes, a comparison by age group (24 months) revealed more advanced age group with higher frequency of group E tumor (15% vs. 25% vs. 32% vs. 39%, P < 0.001). By treatment outcomes, complete tumor control was achieved with chemoreduction alone more often in less advanced age group (46% vs. 30% vs. 17% vs. 8%, P < 0.001). Additional treatment after chemoreduction was needed more often in more advanced age group with external beam radiotherapy (EBRT; 9% vs. 16% vs. 20% vs. 15%, P = 0.006) or enucleation (12% vs. 18% vs. 26% vs. 37%, P < 0.001). Over time (1994-1998 vs. 1999-2003 vs. 2004-2008 vs. 2009-2013 vs. 2014-2019), the paradigm for additional required treatment after chemoreduction shifted toward less EBRT (27% vs. 24% vs. 14% vs. 7% vs. 2%, P < 0.001) and more intra-arterial (0% vs. 0% vs. 1% vs. 25% vs. 48%, P < 0.001) and intravitreal (0% vs. 0% vs. 3% vs. 10% vs. 20%, P < 0.001) chemotherapy.

CONCLUSIONS: Chemoreduction is a safe and effective treatment method for patients with retinoblastoma, demonstrating the best tumor control in the younger age groups.

Recommended Citation

Bas, Zeynep; Dalvin, Lauren A.; Tadepalli, Sameeksha; Rao, Raksha; Shah, Amish; Leahey, Ann M.; and Shields, Carol L., "Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients." (2021). Wills Eye Hospital Papers. Paper 133.
https://jdc.jefferson.edu/willsfp/133

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

33481399

Language

English